MULTIPLE MYELOMA

This study is for people newly diagnosed with multiple myeloma. It uses a sensitive test to measure tiny amounts of cancer left after initial treatment. For those with a deep response, the study tests if they can safely skip a stem cell transplant and take fewer treatments. For o…

This early-phase study tests a new therapy using a patient's own immune cells (T cells) trained to attack proteins found on myeloma cells. It includes people with active multiple myeloma or high-risk precursor conditions (MGUS or smoldering myeloma). The main goals are to find a …

This study tests whether targeted radiation can help control multiple myeloma that remains active after CAR-T cell therapy. About 30 adults who still have signs of disease on scans after CAR-T will receive radiation to up to five tumor spots. The goal is to see if this approach i…

This study tests a drug called elranatamab in people with multiple myeloma that has returned or not responded to previous treatments. About 33 participants who have already tried 1 to 3 other therapies will receive elranatamab alone. The goal is to see if the drug can make cancer…

This study tests whether adding the drug talquetamab after BCMA CAR T-cell therapy can better control multiple myeloma that has come back or not responded to treatment. About 17 adults who have already received the CAR T-cell therapy ide-cel will get talquetamab as a follow-up. T…

This early-stage study is testing a cell therapy called arlocabtagene autoleucel combined with other drugs (alnuctamab, mezigdomide, iberdomide, or elranatamab) in people with multiple myeloma that has returned or stopped responding to prior treatments. The main goals are to find…

This early-phase study tests whether combining teclistamab and mezigdomide is safe and works for people with multiple myeloma that has come back or stopped responding to other treatments. About 18 adults who have already tried at least two prior therapies will take part. The main…

This study tests a new treatment called BCMA-CART, sometimes combined with a stem cell transplant, for young adults (18-55) newly diagnosed with multiple myeloma. The goal is to see how safe and effective it is at controlling the cancer and achieving deep remission. About 50 part…

This early-phase study tests a new drug (JNJ-79635322) combined with standard treatments for multiple myeloma, a blood cancer. About 140 participants will receive different drug combinations to find the safest and most effective dose. The goal is to control the disease, not cure …

This study tests whether adding daratumumab to a standard three-drug regimen can shrink tumors in people whose multiple myeloma has returned or stopped responding to prior treatments. About 43 adults aged 18 to 80 will receive the four drugs in cycles. The main goal is to see how…

This study tests two experimental drugs, etentamig and iberdomide, together in adults whose multiple myeloma has returned or stopped responding to treatment. The goal is to find safe doses and see if the combination can shrink the cancer. About 135 participants will receive diffe…

This study is for older adults with newly diagnosed multiple myeloma who cannot have a stem cell transplant. It compares two treatment plans: taking the drugs daratumumab or isatuximab continuously versus stopping them after about 18 months. The goal is to see if a shorter treatm…

This study is testing several different treatment combinations for people with multiple myeloma, a type of blood cancer. The goal is to see if these treatments are safe and how well they work at shrinking tumors and helping people live longer. About 200 participants will be enrol…

This early-phase study tests a new drug called SHR-9539 for people with multiple myeloma, a type of blood cancer. The main goals are to find a safe dose and check for side effects. About 138 adults with the disease will take part to see how the drug works in the body and if it he…

This study is testing a combination of two drugs, mezigdomide and elranatamab, in about 62 adults with multiple myeloma that has returned or no longer responds to standard treatments. The main goals are to find the safest dose and to see if the combination helps shrink or control…

This study is for people with high-risk multiple myeloma who have already completed initial treatment. It compares two maintenance therapies: a combination of ixazomib and a reduced dose of lenalidomide versus ixazomib alone. The goal is to see which approach better delays cancer…

This study is for people with multiple myeloma that has returned or is no longer responding to standard treatments, including CAR T-cell therapy. Researchers are testing a combination of four drugs (belantamab mafodotin, carfilzomib, pomalidomide, and dexamethasone) to see if it …

This study tests whether taking iberdomide pills after CAR-T cell therapy can keep multiple myeloma under control longer than simply watching and waiting. About 78 adults who have already received the CAR-T treatment idecabtagene vicleucel will be randomly assigned to either take…

This study tests whether a combination of elotuzumab, iberdomide, and dexamethasone can help control multiple myeloma that has returned or not responded to treatment, after patients have already received a CAR-T cell therapy called idecabtagene vicleucel. About 49 adults with rel…

This study looks at a combination of three drugs—daratumumab, pomalidomide, and dexamethasone (Dara-PD)—for people whose multiple myeloma has come back for the first time. The goal is to see how well this treatment controls the disease and delays further progression. About 50 adu…

This study tests several new drug combinations for people newly diagnosed with multiple myeloma who are eligible for a stem cell transplant. The goal is to see if these combinations are safe and work better than current treatments. About 160 adults aged 18 to 70 will take part.

This early-phase study tests a combination of drugs (carfilzomib, cyclophosphamide, dexamethasone, and G-CSF) to collect stem cells for a transplant in people with multiple myeloma. The goal is to find the safest and most effective dose of carfilzomib. About 18 participants will …

This study looks at how HyQvia, a treatment to boost the immune system, is used in real-world clinics for people with multiple myeloma who have a weakened immune system (secondary immunodeficiency). Researchers will track details like dose, infusion speed, and where the treatment…

This study tests a new drug called etentamig combined with daratumumab for people newly diagnosed with multiple myeloma who are not healthy enough for a stem cell transplant. About 660 adults will receive either the new combination or standard treatment. The goal is to see if the…

This study tests whether adding isatuximab to standard lenalidomide therapy after a stem cell transplant can better control high-risk multiple myeloma. About 61 adults aged 18 to 72 with newly diagnosed disease will receive the combination as maintenance treatment. The main goal …

This study tests whether adding a vitamin A derivative (ATRA) to standard carfilzomib therapy can make the cancer respond again in people with multiple myeloma that has stopped responding to carfilzomib. About 42 adults who have tried at least three prior treatments will receive …

This study is testing the safety of a drug called teclistamab in Indian adults with multiple myeloma, a blood cancer that has come back or stopped responding to treatment. Participants must have already tried at least three different types of therapy. The goal is to see how safe …

This early-phase study tests a new treatment called AZD0120 for adults with multiple myeloma, a type of blood cancer. The therapy uses a patient's own immune cells, modified to attack two cancer targets (BCMA and CD19). The main goals are to check safety and find the right dose, …

This study tests whether Darzalex Faspro can safely lower donor-specific antibodies (DSAs) in adults with blood cancers who are at high risk of rejecting a stem cell transplant. Participants receive the drug before standard transplant preparation to reduce DSA levels enough to al…

This study tests two new drug combinations (Tal-P and Tal-Tec) against standard treatments for people with multiple myeloma that has returned or stopped responding after 1 to 4 prior therapies. About 795 participants will be randomly assigned to one of the combinations or standar…

This study tests a new drug, JNJ-79635322, against another antibody treatment for people with multiple myeloma that has returned or stopped responding after at least three prior therapies. About 400 participants will be randomly assigned to one of the two treatments. The goal is …

This study tests whether lower doses of three drugs (isatuximab, lenalidomide, and dexamethasone) can safely and effectively treat newly diagnosed multiple myeloma in patients who are very likely to have severe side effects from standard treatment. The goal is to reduce side effe…

This study tests a new treatment called PD-1Ab21-BCMA CAR-T cells for people with multiple myeloma who also have kidney problems. The treatment uses a patient's own immune cells that are modified in a lab to find and attack cancer cells. The goal is to see if this therapy can kee…

This study tests whether teclistamab, a drug for relapsed/refractory multiple myeloma, can be given safely in an outpatient setting instead of requiring a hospital stay. It involves 15 patients who have already tried at least three other treatments. The goal is to reduce hospital…

This study tests a new treatment called BMS-986453, a type of CAR T cell therapy that targets two proteins on myeloma cells. It is for people who have been recently diagnosed with multiple myeloma and are not planning to have a stem cell transplant. The goal is to see if the trea…

This study tests a drug called belumosudil mesylate, given alone or with dexamethasone, in people whose multiple myeloma has returned or stopped responding to treatment. The first part finds the safest dose, and the second part checks if that dose helps control the cancer. About …

This early-phase trial tests a new type of CAR T cell therapy for people with multiple myeloma that has come back or stopped responding to other treatments. The therapy uses immune cells engineered to recognize and attack myeloma cells through two targets (BCMA and CD19). The mai…

This study tests a new approach to collecting stem cells for transplant in people with multiple myeloma, Hodgkin lymphoma, or non-Hodgkin lymphoma. The goal is to see if using a standard drug alone, with a second drug only when needed, can collect enough stem cells while possibly…

This study tests whether switching between two different drug combinations (Dara-RVd and Tec-RVd) is safe and effective for people newly diagnosed with multiple myeloma. About 65 participants will receive alternating cycles of these therapies. The goal is to achieve undetectable …

This study tests whether a new drug combination (belantamab mafodotin plus lenalidomide and dexamethasone) works better than the current standard treatment (daratumumab plus lenalidomide and dexamethasone) for people newly diagnosed with multiple myeloma who cannot have a stem ce…

This early-phase study tests a new way to prepare the body for CAR T-cell therapy in people with multiple myeloma who also have kidney problems. Standard prep can be hard on the kidneys, so researchers are using a low dose of total body radiation plus a chemotherapy drug (cycloph…

This early-stage study tests two drugs—elranatamab (a shot under the skin) and iberdomide (a pill)—in people whose multiple myeloma has returned or stopped responding to treatment. The goal is to find a safe dose and see how well the combination works. About 87 adults with myelom…

This study looks at whether CAR T cell therapy can be safely given to people with blood cancers who also have moderate to severe kidney problems. Researchers will adjust the standard chemotherapy given before the CAR T cells to protect the kidneys. The goal is to see how often si…

This study tests whether adding the experimental drug linvoseltamab after initial standard therapy works better than continuing standard therapy alone for people with newly diagnosed multiple myeloma who cannot have a stem cell transplant. About 1,000 participants will be randoml…

This early study tests a new injection called JY232 in 9 people whose multiple myeloma has returned or not responded to other treatments. The main goals are to check safety and find the best dose. Researchers will also look for signs that the treatment is shrinking the cancer.

This study tests a new treatment for people with blood cancers like leukemia, lymphoma, or multiple myeloma that have come back or not responded to standard therapy. Participants receive donor immune cells (NK cells) that are engineered to better target cancer, along with chemoth…

This early-phase study tests whether adding the drug mezigdomide after CAR T-cell therapy can help keep multiple myeloma from coming back. About 15 adults whose cancer returned after several prior treatments will receive the drug to see if it is safe and how well it works. The go…

This study tests a new treatment called arlocabtagene autoleucel (BMS-986393) for adults with multiple myeloma that has returned or stopped responding to at least four prior treatments. The therapy uses a patient's own immune cells, modified to attack cancer cells. The goal is to…

This study looks at whether people with multiple myeloma who are in a very deep remission (called MRD-negative) can safely stop their maintenance therapy. About 70 adults who have been on maintenance for at least 2 years will stop treatment and be monitored for 12-24 months. The …

This study tests a combination of four drugs (cyclophosphamide, bortezomib, dexamethasone, and daratumumab) in 20 people with kidney disease caused by abnormal proteins from a blood condition. The goal is to see if the treatment is safe and can improve kidney function. Participan…

This study uses a cord blood transplant after strong chemotherapy and radiation to treat various blood cancers like leukemia and lymphoma. About 200 participants will receive the transplant to see if it improves survival one year later. The approach aims to replace diseased bone …

This study tests if the antiviral drug remdesivir can safely treat RSV (a common respiratory virus) in 60 adults whose immune systems are weakened by cancer treatments or autoimmune therapies. Participants must have a confirmed RSV infection with symptoms. The main goal is to see…

This study tests a new drug, linvoseltamab, in about 387 people whose multiple myeloma has returned or stopped responding to other treatments. The main goals are to check the drug's safety and find the best dose, while also seeing if it can shrink the cancer. Participants must be…

This study tests whether adding cyclophosphamide to elranatamab can improve outcomes for people with multiple myeloma that has returned or stopped responding to treatment, especially those with high-risk features. About 26 participants will receive the drug combination, and resea…

This study tests whether the drug elranatamab, given after CAR T-cell therapy (idecabtagene vicleucel), can lower the chance of multiple myeloma worsening. It enrolls 32 adults with relapsed or refractory multiple myeloma. The goal is to see if this combination improves response …

This study is testing a new drug, CC-92480, combined with other therapies for people whose multiple myeloma has come back or stopped responding to treatment. The goal is to find safe doses and see if the combination can shrink tumors. About 260 participants will take part in this…

This study tests whether a new drug called elranatamab, when combined with two standard drugs (daratumumab and lenalidomide), works better than the usual four-drug combination for people newly diagnosed with multiple myeloma who are not eligible for a stem cell transplant. The st…

This early study tests a new treatment called BCMA-UCART for adults with multiple myeloma that has come back or not responded to other therapies. The treatment uses donor immune cells that are specially designed to find and attack cancer cells. The goal is to see if it is safe an…

This study tests whether adding the drug teclistamab to standard maintenance therapy (lenalidomide) can better prevent multiple myeloma from coming back after a stem cell transplant. About 1,600 adults with newly diagnosed myeloma who have already responded to initial treatment w…

This early-stage trial is testing a drug called venetoclax alongside standard treatments for people with a specific genetic type of multiple myeloma (t(11;14)). The goal is to find the safest dose and see if the combination can better control the cancer. About 100 adults with act…

This study tests a combination of four drugs (isatuximab, belantamab mafodotin, pomalidomide, and dexamethasone) in 50 adults whose multiple myeloma has returned or stopped responding to treatment. The main goal is to see how many patients respond to this drug cocktail. This is n…

This study tests two drug combinations (teclistamab plus daratumumab or lenalidomide) in people aged 65 and older with newly diagnosed multiple myeloma who are not eligible for a stem cell transplant. The goal is to see if these combinations are safe and can achieve a very good p…

This study tests an experimental drug called surzetoclax (ABBV-453) in about 130 adults with multiple myeloma that has returned or stopped responding to prior treatments. The drug is given alone or combined with other anti-myeloma medicines. The main goals are to check safety and…

This early-phase study tests whether adding a personalized cancer vaccine (DC/MM fusion) to standard CAR-T cell therapy is safe and works better for people with multiple myeloma that has come back or not responded to treatment. About 25 adults will receive the vaccine along with …

This study tests three different drug combinations to prevent graft-versus-host disease (GVHD) in 400 people with blood cancers receiving stem cells from unrelated donors. GVHD is a serious complication where donor cells attack the patient's body. The goal is to find which approa…

This study tests an experimental drug, linvoseltamab, in people with newly diagnosed multiple myeloma, a type of blood cancer. The drug aims to shrink tumors and control the disease. About 149 participants will join, and the study will check safety, side effects, and how well the…

This study tests whether a new drug, iberdomide, works better than the current standard lenalidomide as maintenance therapy after a stem cell transplant in people newly diagnosed with multiple myeloma. About 1,200 participants will receive either drug to see which one delays canc…

This study tests a two-step, lower-intensity approach using radiation and chemotherapy before a stem cell transplant for people with various blood cancers or disorders. The goal is to see if this gentler preparation reduces the risk of death from the transplant itself. About 63 p…

This study tests a new medicine called elranatamab, given as a weekly shot, against standard drug combinations for multiple myeloma that has returned or not responded to prior treatments. About 492 adults whose cancer progressed after anti-CD38 therapy will take part. The goal is…

This study tests whether a two-step immunotherapy approach can eliminate remaining cancer cells in people with newly diagnosed multiple myeloma who still have detectable disease after initial treatment. Participants first receive talquetamab, and if that doesn't clear the cancer,…

This study tests whether combining two drugs (teclistamab or talquetamab with daratumumab) can delay or prevent multiple myeloma in 50 people with high-risk smoldering myeloma. Participants receive the drug combination and are monitored for side effects and whether the cancer bec…

This study tests whether giving the drug belantamab mafodotin less often, combined with other standard cancer medicines, can still control multiple myeloma (a blood cancer) while causing fewer eye-related side effects. About 200 adults whose cancer has returned or stopped respond…

This study tests a new treatment called GC012F for people with multiple myeloma that has come back or stopped responding to other therapies. GC012F uses a patient's own immune cells, which are modified in a lab to better find and attack cancer cells. The goal is to control the di…

This expanded access program provides a CAR T-cell therapy called ide-cel to people with multiple myeloma whose specially made treatment batch did not meet commercial standards. The goal is to offer a treatment option when no other suitable therapy is available. Participants must…

This study tests whether the drug selinexor can help keep multiple myeloma from coming back after CAR-T cell therapy. About 20 people with high-risk myeloma who have already had CAR-T will take selinexor pills. The goal is to see if this maintenance approach is safe and can lead …

This study tests whether giving immune globulin (IGI) regularly can prevent serious infections in people with multiple myeloma who are receiving a type of immunotherapy called bispecific antibodies. About 183 adults will be randomly assigned to receive IGI for 12 months from the …

This study tests a powerful two-step treatment for people with an aggressive form of multiple myeloma that didn't respond well to first-line therapy. First, patients receive their own stem cells (a stem cell transplant), followed by an infusion of their own genetically modified i…

This study tests a personalized approach for people with newly diagnosed multiple myeloma who have had a stem cell transplant. After transplant, participants receive a drug called elranatamab as maintenance therapy, with the dose and duration guided by a sensitive blood test that…

This early-phase trial tests a combination of three drugs—talquetamab, iberdomide, and dexamethasone—in 32 adults whose multiple myeloma has returned or stopped responding to prior treatments. The goal is to find the safest dose and check for side effects. Participants must have …

This program offers a CAR-T cell therapy called cilta-cel to people with multiple myeloma who have no other good treatment options. It is for patients whose disease is serious or life-threatening and who cannot get the standard version of this therapy. The goal is to provide acce…

This study tests whether adding siltuximab (a drug that blocks a protein called IL-6) to a personalized dose of melphalan chemotherapy works better than the standard dosing method for people over 60 with multiple myeloma who are getting a stem cell transplant. The goal is to impr…

This study tests whether adding targeted radiation to the drug talquetamab can safely and effectively treat multiple myeloma that has spread to organs or soft tissues (extramedullary disease). About 20 adults with this difficult-to-treat condition will receive radiation to one tu…

This study looks at how well umbilical cord blood stem cells from unrelated donors can restore blood cell counts in people with serious blood cancers, immune deficiencies, or genetic disorders. Researchers will track how often the transplant succeeds, how long it takes for blood …

This early-phase study tests a new type of cell therapy (CAR19-BCMA CAR-T) for people with multiple myeloma that has come back or stopped responding to treatment. The therapy uses a patient's own immune cells, modified to attack two targets on cancer cells. The main goal is to ch…

This study tests whether people with newly diagnosed multiple myeloma or amyloidosis who achieve a very deep response to initial drug therapy can safely postpone a stem cell transplant. About 40 participants will receive 6 cycles of a powerful drug combination (Dara-VRD). Those w…

This study tests whether adding a newer drug (teclistamab or talquetamab) to standard therapy can better control newly diagnosed multiple myeloma in people who are not eligible for a stem cell transplant. About 1,590 participants will be randomly assigned to one of three treatmen…

This study is testing whether combining two already-approved multiple myeloma drugs—belantamab mafodotin and elotuzumab—is safe and more effective than using them alone. About 24 adults whose myeloma has returned or not responded to at least three prior treatments will take part.…

This early-stage study tests an experimental pill called KTX-1001 in people with multiple myeloma that has returned or not responded to at least three prior treatments. The main goals are to check safety and find the right dose, with early signs of tumor shrinkage also measured. …

This study tests a cell therapy called cilta-cel for people with multiple myeloma, a type of blood cancer. Researchers want to see if using a different chemotherapy before the infusion can make the treatment work better and cause fewer side effects. About 60 participants will be …

This study tests whether adding motixafortide to standard G-CSF helps collect more stem cells for a patient's own transplant. About 60 adults with multiple myeloma will receive either the drug combo or a placebo. The goal is to see if the combo leads to enough stem cells in fewer…

This study tests a new treatment called anitocabtagene autoleucel (a type of cell therapy) against the usual treatments for multiple myeloma that has returned or not responded to prior therapy. About 450 adults who have already tried 1 to 3 prior treatments will be randomly assig…

This early-stage study tests an experimental drug called linvoseltamab combined with other cancer treatments for people with multiple myeloma that has come back after prior therapy. The main goal is to see if these combinations are safe and to find the right doses. About 317 part…

This study tests a combination of three drugs (carfilzomib, iberdomide, and dexamethasone) in people newly diagnosed with multiple myeloma who are eligible for a stem cell transplant. The goal is to see if this treatment is safe and effective at reducing cancer before the transpl…

This early-stage study tests an experimental drug called ABBV-438 in about 127 adults whose multiple myeloma has returned or stopped responding to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink the cancer. Particip…

This study tests a combination of four drugs (daratumumab, bortezomib, cyclophosphamide, and dexamethasone) in people newly diagnosed with multiple myeloma who also have kidney failure. The goal is to see how well the treatment shrinks the cancer and improves kidney function. Abo…

This study tests an experimental drug called JNJ-79635322 in people with multiple myeloma whose cancer came back or didn't respond after at least three prior treatments. The main goal is to see how many patients' tumors shrink or disappear. About 157 adults will take part, and re…

This program provides early access to venetoclax, a targeted therapy for several blood cancers including chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), and multiple myeloma. It is for people who have no other suitable treatments and cannot join a clinical trial…

This study tests an experimental drug called etentamig (ABBV-383) in adults with multiple myeloma that has returned or not improved after prior treatments. The goal is to find the best dose and check for side effects. About 210 participants will receive the drug by IV infusion ov…

This study tests an experimental drug called belantamab, alone or with other treatments, in people with multiple myeloma (a type of blood cancer). It includes 153 adults whose cancer has returned or not responded to prior therapies. The goal is to find safe doses and see how well…

This study tests an experimental drug, etentamig, for adults with multiple myeloma, a blood cancer that often returns or resists treatment. About 440 participants worldwide will receive etentamig alone or combined with other cancer drugs to find safe doses and check if it shrinks…

This early-phase study tests a new CAR-T cell therapy that targets a protein called CS1 on multiple myeloma cells. It is for patients whose cancer has returned or not responded to at least three prior treatments. The goal is to check the treatment's safety and see how well it con…

This study tests two drugs, vemurafenib and cobimetinib, already approved for melanoma, in adults with other rare cancers that have a specific BRAF V600 gene change. About 30 people will take the drugs to see if their tumors shrink or stop growing. The goal is to find new uses fo…

This study tests a personalized gene therapy for people with metastatic cancers that haven't responded to standard treatments. Doctors take a patient's own white blood cells, genetically engineer them in a lab to recognize and attack unique mutations in their tumor, and then infu…

This study tests a new combination of drugs (epunamin plus DECP) in 48 adults with relapsed/refractory multiple myeloma, a blood cancer that has come back or stopped responding to treatment. The goal is to see if this combo can shrink tumors and improve outcomes. Participants mus…

This early-phase trial tests a combination CAR-T cell therapy that targets two cancer markers (BCMA and GPRC5D) in people with high-risk multiple myeloma or plasmacytoma. The goal is to see if this treatment is safe and can control the disease as a first-line therapy. About 20 pa…

This early-phase study tests a new treatment called TriPRIL CAR T cells for people with multiple myeloma that has come back or not responded to standard therapy. The main goal is to check safety and side effects in 18 adults. Participants first receive chemotherapy to prepare the…

This study tests a new drug called cemsidomide combined with dexamethasone in 100 adults whose multiple myeloma has returned or stopped responding after at least three prior treatments. The goal is to see how well the combination shrinks tumors and how safe it is. Participants wi…

This study tests whether adding isatuximab to iberdomide maintenance therapy works better than iberdomide alone for people with newly diagnosed multiple myeloma after a stem cell transplant. About 411 participants will be randomly assigned to one of two treatment groups. The main…

This study tests whether a medicine called IgPro20 can help prevent infections in people with multiple myeloma who have low antibody levels due to treatment with bispecific antibodies. About 100 participants will either receive IgPro20 or standard care, and researchers will compa…

This study is testing whether a specific diet can improve how well standard chemotherapy works and how patients feel. About 220 adults with newly diagnosed multiple myeloma will be randomly assigned to a dietary plan or usual care. Researchers will measure treatment response and …

This study looks at whether people with relapsed multiple myeloma can safely give themselves the drug elranatamab at home instead of going to a clinic. About 20 participants will be trained to self-inject and will track side effects, time spent, and any unplanned hospital visits.…

This program provides the experimental drug selinexor to people with multiple myeloma, lymphoma, sarcoma, or other cancers who have run out of standard treatments and cannot join a clinical trial. The goal is to offer a potential treatment option when nothing else is left. Patien…

This study tests a new drug called elranatamab, alone or with another drug (daratumumab), in people whose multiple myeloma has returned after at least one prior treatment. About 944 participants will be randomly assigned to one of three treatment groups. The goal is to see if elr…

This study tests whether a new drug called GR1803 works better than the standard combination of daratumumab, pomalidomide, and dexamethasone (DPd) for people with multiple myeloma that has returned or stopped responding after 1 to 3 prior treatments. About 358 adults will be rand…

This study tests a new drug called AZD0305, alone or with other cancer drugs, in about 226 adults with multiple myeloma. The goal is to check safety, find the right dose, and see if it helps control the cancer. Participants must have confirmed multiple myeloma and be in good enou…

This early-phase study is testing whether it is safe and possible to collect a patient's own stem cells and give them together with CAR T-cell therapy for blood cancers that have come back or not responded to treatment. About 20 adults aged 18 to 85 with certain types of lymphoma…

This study tests a new combination of drugs (iberdomide, bortezomib, dexamethasone, and isatuximab) for people with newly diagnosed multiple myeloma who are not eligible for a stem cell transplant. The goal is to see if this treatment can achieve a very deep response (stringent c…

This study looks at whether plasma exchange or newer drugs like daratumumab can help the kidneys recover in people with multiple myeloma who have a type of kidney damage called light chain cast nephropathy. About 450 adults with this condition will be followed for 90 days to see …

This study tests a combination of three drugs—elranatamab, lenalidomide, and dexamethasone—in people newly diagnosed with multiple myeloma, a blood cancer. The goal is to see if this treatment can eliminate all signs of cancer in the bone marrow. About 104 participants will recei…

This study tests a new daily pill, LP-118, in up to 100 people with blood cancers that have come back or not responded to treatment. The main goal is to find the safest dose and see how the drug works in the body. Early results will also hint at whether it can shrink tumors or sl…

This study tests whether adding linvoseltamab to the standard maintenance drug lenalidomide can eliminate leftover cancer cells in people with multiple myeloma. It includes two groups: those with stable disease and those whose cancer has returned. The goal is to achieve or regain…

This study offers ongoing access to daratumumab for up to 500 multiple myeloma patients who are already benefiting from it in other studies. Participants will continue their treatment while researchers monitor long-term safety, including serious side effects and infections. The g…

This study tests whether a prebiotic (resistant starch) can improve gut microbiome diversity in 30 people with multiple myeloma or lymphoma undergoing autologous stem cell transplant. Participants take the prebiotic or a placebo for about 10 days before and until engraftment. The…

This study tests a new drug called CCS1477 (inobrodib) in people with advanced blood cancers like leukemia, lymphoma, and multiple myeloma. The goal is to see if the drug is safe and can help control the disease. About 250 participants who have tried standard treatments without s…

This study tests whether two drugs, teclistamab and talquetamab, can be given safely in a clinic or doctor's office instead of requiring a hospital stay for multiple myeloma patients. About 100 adults who have already tried other treatments will receive these drugs along with med…

This early study tests a new type of CAR T-cell therapy for adults with blood cancers like leukemia, lymphoma, and multiple myeloma that have returned or not improved with standard treatments. The therapy uses a patient's own immune cells, modified to attack cancer cells. The mai…

This study tests a combination of four drugs (bortezomib, isatuximab, cyclophosphamide, and dexamethasone) as an initial treatment for people with multiple myeloma who also have kidney problems and are eligible for a stem cell transplant. The goal is to see how well this treatmen…

This study tests a personalized treatment approach for people aged 65 and older who are newly diagnosed with multiple myeloma. The treatment plan is adjusted based on each patient's frailty level, aiming to improve response rates and reduce the chance of stopping treatment due to…

This study tests whether giving the drug elranatamab before and after a stem cell transplant can better control high-risk multiple myeloma. About 40 adults with newly diagnosed, high-risk myeloma will receive the drug to reduce cancer cells before transplant and then as maintenan…

This study tests an experimental drug called enzomenib in about 600 people with acute leukemia and certain other blood cancers. The goal is to find the safest dose and see if the drug can shrink or control the cancer. Participants must have cancers that came back or did not respo…

This study offers ongoing access to the drug elranatamab for people with multiple myeloma who were already benefiting from it in earlier Pfizer studies. About 80 participants will continue treatment and be monitored for side effects. The goal is to keep providing the drug while c…

This study tests a new drug called etentamig against standard treatments for adults with multiple myeloma that has returned or stopped responding. About 380 participants will receive either etentamig or a standard therapy chosen by their doctor. The goal is to see if etentamig ca…

This early-stage trial tests a drug called cevostamab in about 20 Chinese adults whose multiple myeloma has returned or stopped responding to standard treatments. The main goals are to check the drug's safety and how the body processes it. Researchers will also watch for signs th…

This is the first study in people testing a new drug called TQB2934 for multiple myeloma, a type of blood cancer. The main goal is to check if the injection is safe and to see how the body processes it. The drug works by connecting a patient's own immune cells to the cancer cells…

This study is testing whether a two-drug maintenance therapy can help control multiple myeloma in patients who still have small amounts of cancer cells after a stem cell transplant. The treatment involves regular infusions of one drug and daily pills of another, taken long-term t…

This early-stage study is testing whether a personalized cancer vaccine made from a patient's own cells, when combined with an immunotherapy drug called elranatamab, is safe and effective for treating multiple myeloma that has returned or stopped responding to standard treatments…

This early-stage trial is testing the safety and best dose of a new cell therapy for multiple myeloma that has returned or stopped responding to other treatments. Doctors take a patient's own immune cells, use CRISPR gene-editing technology to reprogram them to hunt down cancer c…

This early-stage study is testing a new cell therapy called LVIVO-TaVec200 for patients with multiple myeloma that has returned or stopped responding to at least three prior treatments. The main goals are to find a safe dose, see how the body handles the treatment, and check for …

This early-stage study tests a new radioactive imaging agent called [89Zr]DFO-YS5 to see if it can safely and accurately detect multiple myeloma cells that have a specific protein (CD46). About 20 adults with confirmed multiple myeloma will receive the agent and undergo PET scans…

This early-phase study tests a new PET imaging probe called 68Ga-NB381 that targets a protein (CD38) found on multiple myeloma cancer cells. The goal is to see if this scan can detect the disease more accurately than current methods, potentially reducing the need for invasive bon…

This study aims to find multiple myeloma at its earliest, precancerous stage (MGUS) in people at higher risk—Black adults and those with a family history of plasma cell disorders. By screening with a simple blood test, researchers hope to catch the disease before it causes seriou…

This study is testing a blood test that looks for DNA signals from 20 different cancers, including breast, lung, and colon cancer. Researchers want to see if the test can find cancer early, detect any cancer left after treatment, and catch a relapse before symptoms appear. About …

This study is testing a new platform that uses advanced testing to better understand different types of cancer, including leukemia, myeloma, and solid tumors. The goal is to see if this platform can change the recommended treatment for patients, making it more personalized. About…

This study looks at why people with multiple myeloma fall and tests a home exercise program to prevent falls. About 60 adults on cancer therapy will use a training app for 24 weeks. The goal is to find fall risks and see if the exercises are practical and reduce fear of falling.

This study looks at whether adding early palliative care to usual treatment helps people with multiple myeloma or aggressive lymphoma feel better. About 144 patients and their caregivers will either get early palliative care or standard care alone. Researchers will track quality …

This study is for people with multiple myeloma whose doctors recommend radiation. Normally, radiation takes 2-3 weeks, but this trial tests a shorter course (hypofractionation) with slightly higher daily doses to see if it is safe. About 30 participants will receive pelvic radiat…

This study tests whether an 8-week home exercise program, done before a stem cell transplant, can improve muscle strength and physical fitness in people with multiple myeloma. Thirty participants will either exercise or continue normal activities. The goal is to see if pre-transp…

This study tests whether a home-based program combining gentle physical activity, mindfulness, and telephone health coaching can reduce fatigue and improve quality of life in people aged 65 and older with multiple myeloma. Participants will use a remote monitoring device and rece…

This study tests whether a thorough health check (geriatric assessment) before CAR-T therapy can guide personalized support—like physical therapy, nutrition advice, and mental exercises—to help adults aged 60 and older recover faster. Participants have B-cell non-Hodgkin lymphoma…

This study looks at whether adding a special palliative care program (called PEACE) to usual cancer care can help adults with lymphoma, leukemia, or multiple myeloma who are receiving cell therapy. About 90 participants will be randomly assigned to either get PEACE plus standard …

This study tests whether a tailored exercise program can reduce fatigue and improve quality of life in 120 adults with multiple myeloma who are about to receive a stem cell transplant. Participants will follow a personalized physical activity plan designed to be easy and acceptab…

This study looks at whether a diet that includes longer overnight fasting and follows a Mediterranean eating pattern is possible for people with multiple myeloma or its early forms (MGUS or smoldering myeloma). Researchers want to see if participants can stick with the diet and i…

This study tests a 'go-slow' approach for ultra-frail patients newly diagnosed with multiple myeloma. Instead of starting all drugs at once, treatment begins with just two medications (isatuximab and dexamethasone), then adds a third (lenalidomide) after two months. The goal is t…

This study compares giving cancer treatment at home versus in a clinic for 27 adults with various cancers in the Florida Panhandle. The goal is to see if patients prefer home care and if it is safe. Participants will receive their usual cancer drugs either at home or in the clini…

This study tests whether a prehabilitation (prehab) program can help adults aged 60 and older with multiple myeloma maintain physical function before and after a stem cell transplant. Thirty participants will be randomly assigned to either the prehab program or a control group. T…

This study tests whether adding a non-opioid painkiller (ketorolac) to standard opioid pain medicine can reduce the amount of opioids needed after preventive thigh bone surgery. The surgery is for patients with cancer that has spread to the thigh bone but who do not have a broken…

This study compares giving cancer treatment at home versus in a clinic for people with advanced cancers. The goal is to see if home treatment reduces stress, financial burden, and improves the overall experience. About 220 participants will be randomly assigned to receive their t…

This study tests if certain preventive treatments can reduce or prevent taste changes caused by a multiple myeloma drug called talquetamab. About 210 people with multiple myeloma will be randomly assigned to different preventive strategies. The goal is to improve quality of life …

This study tests whether a new combination of anti-nausea drugs (fosaprepitant, tropisetron, and olanzapine) works better than the standard combo (fosaprepitant, tropisetron, and dexamethasone) for preventing delayed nausea and vomiting after high-dose chemotherapy in multiple my…

This study looks at whether people with multiple myeloma can and want to join a 10-week exercise program while getting chemotherapy before a stem cell transplant. The program includes both in-person and online sessions. Researchers want to see if it helps maintain physical fitnes…

This study compares two premedication regimens—methylprednisolone versus dexamethasone—to prevent allergic reactions to motixafortide in multiple myeloma patients undergoing stem cell collection. About 94 adults will participate to see which steroid works better and has fewer sid…

This study tests whether the drug budesonide can prevent severe diarrhea in people with multiple myeloma who are receiving a stem cell transplant. About 120 adults will be randomly assigned to get either budesonide or a placebo alongside standard care. The goal is to see if the d…

This study is creating a large database of up to 5,000 people in Ohio with plasma cell disorders like multiple myeloma and amyloidosis. Researchers will track treatments, outcomes, and quality of life, while also offering patients access to expert consultations and information ab…

This study is creating a large collection of blood, urine, and tissue samples from people with or suspected of having amyloid diseases. The goal is to store these samples and related health data for future laboratory research. No treatments or interventions are given. Up to 10,00…

This study is a registry that collects information from 1,000 patients with blood diseases who receive stem cell transplants at a hospital on the Qinghai-Tibet Plateau. Researchers will track their health, treatments, and costs over time to learn how high altitude affects recover…

This study looks at a specific gene (IGLV1-44) to understand why it causes two rare diseases: AL amyloidosis and POEMS syndrome. Researchers will analyze blood and bone marrow samples from 100 adults with these conditions or multiple myeloma. The goal is to find genetic patterns …

This study tracks 300 firefighters aged 40-49 with at least 5 years on the job to see if exposure to hazardous compounds increases early signs of blood cancers. Researchers will test for pre-cancerous conditions like clonal hematopoiesis and monoclonal gammopathy. The goal is to …

This study tests a decision-support tool called PRIME for adults aged 60 and older with blood cancers like lymphoma, leukemia, or multiple myeloma. The tool helps patients clarify their personal values and shares that information with their doctors. The goal is to see if using PR…

This study looks at how the blood thinner apixaban affects blood clotting in two groups: people newly diagnosed with multiple myeloma and people recovering from total knee replacement surgery. Both groups are at high risk for dangerous blood clots. By comparing how the drug works…

This study looks at whether CAR-T cell therapy, a new immune treatment for blood cancers, can cause early heart problems. Researchers will use ultrasound to check the heart function of 60 patients before and within a few days after treatment. The goal is to find out how often the…

This study collects tissue and fluid samples (like blood, urine, and tumor biopsies) from up to 5,000 children and adults with cancer. The samples are used for research to better understand cancer and develop new tests or treatments. Participants do not receive any experimental t…

This study aims to understand why some people with multiple myeloma relapse early after CART cell therapy. Researchers will analyze specific immune cells called monocytes before and after treatment to see if they predict how well the therapy works. The study will involve 25 parti…

This study is building a registry of 2,000 adults with plasma cell disorders, such as multiple myeloma and amyloidosis. Participants fill out health questionnaires and may give a blood sample to study aging markers. The goal is to gather information to help future research, not t…

This study watches how older patients (60+) with certain blood cancers handle standard CAR T therapy and how it changes their quality of life. No extra treatment is given—just regular care and check-ins. The goal is to see if patients can complete all planned visits before their …

This study follows up to 500 people who received CAR-T cell therapy for blood cancers like leukemia, lymphoma, or multiple myeloma. Researchers will track participants for up to 15 years to see if any new cancers develop. The goal is to understand the long-term safety of this tre…

This study looks at whether using a simple early warning score (based on vital signs like heart rate and oxygen levels) can help doctors identify blood cancer patients who are getting sicker and need intensive care. The goal is to see if moving these patients to the ICU sooner ca…

This study is for people with multiple myeloma who have been on maintenance therapy for at least two years after a stem cell transplant. Researchers want to see if patients whose cancer is undetectable (MRD-negative) can safely stop taking their daily medication without the cance…

This study is building a large registry of 2200 multiple myeloma patients in Germany. Researchers will collect information on treatments, test results, and quality of life over time. The goal is to understand how the disease is actually managed in routine care and what outcomes p…

This study aims to collect information from cancer patients (breast, lung, ovarian, multiple myeloma, or AML) using weekly online surveys about their symptoms. The goal is to build a database that helps doctors better understand and manage side effects during treatment. Participa…

This study looks at tumor samples from 50 people who received a Bristol-Myers Squibb gene-modified cell therapy for blood cancers like lymphoma or myeloma and later developed a second cancer. Researchers will test these samples to see if any therapy-related genes are present. The…

This study enrolls 30,000 people at high risk for multiple myeloma—those with early blood abnormalities (MGUS or smoldering myeloma) or a family history of blood cancers. Researchers will follow participants over time to learn which factors lead to progression to active myeloma. …

This study aims to uncover the genetic roots of lymphomas, leukemias, multiple myeloma, and similar diseases by collecting DNA and blood samples from people who have these conditions and their family members. Researchers will analyze the samples to find genes that increase the ri…

This study looks at whether cancer drugs that target specific gene changes in a tumor can help people with advanced cancers that have not responded to standard treatments. About 720 adults with solid tumors, multiple myeloma, or certain lymphomas will receive a drug matched to th…

This study tests whether a new radioactive tracer called 18F-fluciclovine can detect multiple myeloma better than the current standard tracer on PET/CT scans. About 60 adults with newly diagnosed or relapsed/refractory multiple myeloma will receive both tracers and have their sca…

This study is testing whether an AI tool can create a personalized list of questions for people with lymphoma or multiple myeloma to use during their doctor appointments. About 40 participants will use the AI-generated list and then report how confident they felt communicating an…

This study looks at how common sleep apnea is in people with MGUS or multiple myeloma, and whether it changes gene activity in bone marrow. Researchers will collect bone marrow samples during routine biopsies from 200 participants. The goal is to understand the link between sleep…

This study follows about 295 people with multiple myeloma who have already received the cell therapy cilta-cel. The goal is to watch for delayed side effects, such as new cancers, nerve problems, or serious infections. No new treatment is given—participants are simply monitored o…

This study gathers basic survival and complication information from 2000 people receiving stem cell transplants for blood cancers or immune diseases. The goal is to build a database for future research and to improve patient care. No new treatments are being tested; only standard…

This study follows 700 people with multiple myeloma who are on chemotherapy to see how cannabis (marijuana) use affects their quality of life, symptoms, and side effects. Researchers will compare cannabis users to non-users over time using surveys and medical reports. The goal is…

This study is creating a large database of people in China with various blood diseases, such as leukemia, multiple myeloma, and hemophilia. Researchers will collect information from medical records and follow participants over time to learn about disease patterns, treatments, and…

This early-phase study is testing a new imaging agent called [68Ga]-pentixafor to see how well it lights up certain blood cancers and solid tumors on PET/CT scans. About 30 people with conditions like multiple myeloma, non-Hodgkin lymphoma, or histiocytic neoplasms will receive t…

This study aims to understand why multiple myeloma affects African American, Latino, Asian American, and White patients differently. Researchers will survey 4000 people diagnosed with multiple myeloma in California to learn about factors that may influence the disease and surviva…

This study collects blood and tissue samples from 6,000 people with multiple myeloma, smoldering myeloma, plasma cell leukemia, or MGUS. Researchers will store these samples in a biobank to study the diseases and improve future care. Participants do not receive any treatment as p…

This study will look at the genetic makeup of multiple myeloma tumors in 100 people. Participants will give blood, cheek swab, and tumor samples during their regular care. The goal is to find genetic changes that could lead to new treatments. This study does not provide treatment…

This study looks at how sugar molecules attached to proteins might cause or worsen AL amyloidosis, a rare disease where abnormal proteins build up in organs. Researchers will collect blood and bone marrow samples from 100 adults with related conditions to understand this process.…

This study is testing a drug called Imuthiol (Zn-DDC) in the lab to see how well it kills blood cancer cells, including hard-to-treat cancer stem cells. Researchers will also combine it with other drugs like lenalidomide and pomalidomide. The goal is to find effective, affordable…

This study looks at how gene changes (called germline and somatic variants) affect low blood cell counts after CAR-T therapy in people with multiple myeloma or certain lymphomas. About one-third of patients have low blood counts that last more than 30 days after treatment. Resear…

This study looks at whether giving targeted drugs based on a tumor's specific gene changes can help people with advanced cancer who have run out of standard treatments. It includes adults and teens with solid tumors, multiple myeloma, or non-Hodgkin lymphoma. The goal is to learn…

This study is testing whether daily voice recordings made on a smartphone can help doctors spot early signs of a brain-related side effect called ICANS in people receiving CAR T-cell therapy for lymphoma or multiple myeloma. About 20 participants will record their voice twice a d…

This study looks at how a plant-based diet or supplements (omega-3, curcumin, or probiotics) change butyrate levels in stool after 2 weeks. Butyrate is a substance made by gut bacteria that may affect health. The study includes 200 adults with smoldering multiple myeloma or MGUS,…

This study is building a registry of 5,000 adults aged 50 and older with blood cancers like multiple myeloma and lymphoma. Researchers will track frailty and other age-related health issues using surveys and simple physical tests. The goal is to learn more about this group to gui…

This study collects blood, bone marrow, and tumor samples from 500 adults with cancer or pre-cancerous conditions. Researchers will use these samples to learn more about how cancers grow and why they respond differently to treatments. The goal is to develop more effective therapi…

This study looks at why some families have more blood cancers like lymphoma, leukemia, and myeloma. Researchers will study the genes and environment of 3000 people who have at least two living relatives with these cancers. The goal is to find inherited factors that raise risk, no…

This study is following 1,000 adults with early signs that can lead to multiple myeloma (a blood cancer). The goal is to learn why some people's condition gets worse while others stay stable. Researchers will use advanced genetic tests to look for key changes in the bone marrow. …

This study watches how well a combination of three drugs (selinexor, bortezomib, and dexamethasone) works for adults with multiple myeloma who have already tried 1 to 3 other treatments. It does not test a new drug but collects information from regular medical care to see how lon…

This study collects blood, urine, bone marrow, and tissue samples from adults with lymphoid cancers or precancerous conditions. The goal is to help researchers better understand these diseases, which may lead to new ways to diagnose or treat them. No treatment is given as part of…

This study is testing whether a monthly monitoring program called ICOPE can help detect early signs of decline in people over 70 with multiple myeloma. The program uses digital tools like an app or chatbot to track health changes. The goal is to see if patients can stick with the…

This study is creating a large database of medical information and biological samples from adults with or at risk for many types of cancer, as well as healthy volunteers. The goal is to help researchers better understand what causes cancer, how it progresses, and how to improve p…

This study looks at whether CAR-T cell therapy reduces the protection that vaccines (like measles, mumps, and rubella) provide in people with multiple myeloma and non-Hodgkin lymphoma. Researchers will measure antibody levels before and after CAR-T treatment in 45 adults. The goa…